Human Reproduction, Vol. 16, No. 11, 2258-2262,
November 2001
© 2001 European Society of Human Reproduction and Embryology
Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist
Infertility Unit, Department of Obstetrics and Gynaecology, University of Milan, Via Manfredo Fanti 6, 20122 Milan, Italy
BACKGROUND: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. METHODS: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of 
14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. RESULTS: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P < 0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B. CONCLUSION: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.
Key words: GnRH antagonist/infertility/intrauterine insemination/luteal phase
1 To whom correspondence should be addressed. E-mail: ragni{at}telemacus.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The ESHRE Capri Workshop Group Intrauterine insemination Hum. Reprod. Update, May 1, 2009; 15(3): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.M. Fatemi, B. Popovic-Todorovic, E. Papanikolaou, P. Donoso, and P. Devroey An update of luteal phase support in stimulated IVF cycles Hum. Reprod. Update, November 1, 2007; 13(6): 581 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial Hum. Reprod., February 1, 2007; 22(2): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, M. Anselmino, A.E. Nicolosi, M.E. Brambilla, G. Calanna, and E. Somigliana Follicular vascularity is not predictive of pregnancy outcome in mild controlled ovarian stimulation and IUI cycles Hum. Reprod., January 1, 2007; 22(1): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Allegra, A. Marino, F. Coffaro, P. Scaglione, F. Sammartano, G. Rizza, and A. Volpes GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial Hum. Reprod., January 1, 2007; 22(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G M Beckers, P. Platteau, M. J Eijkemans, N. S Macklon, F. H de Jong, P. Devroey, and B. C J M Fauser The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women. Eur. J. Endocrinol., August 1, 2006; 155(2): 355 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen GnRH antagonists in ovarian stimulation for IVF Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Pelinck, N.E.A. Vogel, A. Hoek, E.G.J.M. Arts, A.H.M. Simons, and M.J. Heineman Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study Hum. Reprod., March 1, 2005; 20(3): 642 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.L. Gomez-Palomares, B. Julia, B. Acevedo-Martin, M. Martinez-Burgos, E.R. Hernandez, and E. Ricciarelli Timing ovulation for intrauterine insemination with a GnRH antagonist Hum. Reprod., February 1, 2005; 20(2): 368 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, F. Alagna, C. Brigante, A. Riccaboni, M. Colombo, E. Somigliana, and P.G. Crosignani GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages Hum. Reprod., January 1, 2004; 19(1): 54 - 58. [Abstract] [Full Text] [PDF]
|
|